Conveners
Topic8-1
- Hiroshi Imao (RIKEN)
-
Roberto LOSITO (CERN)06/11/2023, 10:45Invited Oral
Following the 2020 update of the Strategy for Particle Physics, CERN initiated, under the auspices of the European Large National Laboratories Directors Group (LDG) a new International collaboration to progress on the feasibility studies of a Muon Collider at 10+ TeV with the goal of publishing a pre-CDR report in time for the next ESPPU at the end of the decade. The Collaboration elaborated...
Go to contribution page -
Hiromitsu Haba (Nishina Center for Accelerator-Based Science, RIKEN)06/11/2023, 11:15Invited Oral
Astatine-211 with the half-life of T1/2 = 7.214 h is one of the promising radionuclides for targeted α-particle therapy (TAT) [1]. The 5.87- and 7.45-MeV α-particle emissions occur in intensities of 41.8% and 58.2%, respectively, associated with the 211At decay. Due to the proper ranges of these α-particles in tissue, the 211At-labeled medicine is effective in killing cancer cells. 211At is...
Go to contribution page -
Yasushi Abe (RIKEN)06/11/2023, 11:45Contributed Oral
Electron-beam-driven RI separator for SCRIT (ERIS) [1] was constructed as an online isotope separator (ISOL) system that is dedicated to produce a radioactive isotope (RI) beam for the SCRIT (Self-Confinement RI Target) electron scattering facility [2] at RIKEN RI Beam Factory. Electron scattering is one of the best ways to accurately understand the internal structure of atomic nuclei. The aim...
Go to contribution page -
Ferran Boix Pamies (TRIUMF)06/11/2023, 12:00Contributed Oral
The ISAC facility’s RIB production scheme enables the irradiation and PIE of secondary (parasitic) targets under high power beam conditions (500 MeV, 100 μA), with potential for a wide range of investigations. Over recent years, ISAC has successfully commissioned and routinely operated secondary targets, seamlessly integrating a secondary irradiation program into the primary RIB target...
Go to contribution page